WebDec 20, 2016 · PsiOxus Therapeutics aims to be the world’s leading immuno-oncolytic virus company, delivering medicines of value to patients with cancer. Our work is product and … WebPsiOxus Therapeutics Ltd. Headquarters: Abingdon, United Kingdom Website: http://www.psioxus.com Year Founded: 2006 Status: Private BioCentury Dec 8, 2024 Management Tracks Tak lands at Candel, with plans to speed up development of immunotherapy’s play late-stage assets
PsiOxus on LinkedIn: #cancerresearch #reprogramming #tme
WebJan 5, 2024 · CAMBRIDGE, Mass. & OXFORD, England--(BUSINESS WIRE)-- Akamis Bio (formerly PsiOxus Therapeutics), a clinical-stage oncology company leveraging its Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer, today announced a $30 million convertible note financing co-led by a … WebPsiOxus Therapeutics aims to be the world’s leading cancer gene therapy company to deliver medicines of value to patients with cancer. The company focuses on the discovery … shorten commute
PsiOxus is no more: Meet Akamis Bio - fiercepharma.com
PsiOxus Therapeutics has changed its name to Akamis Bio. Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer. WebApr 16, 2015 · (PsiOxus), an Oxford, UK based biotechnology company developing innovative oncolytic immuno-oncology treatments for cancer, has expanded two of its on-going phase I studies using its anti-cancer treatment candidate, enadenotucirev (EnAd), an oncolytic Ad11/Ad3 chimeric group B adenovirus. The expanded studies, introduce a … WebJul 9, 2012 · PsiOxus’ lead clinical-stage candidate, MT-102, was originally developed by Myotec. The small molecule drug is an anabolic catabolic transforming agent (ACTA) in Phase II development for treating... shorten command line找不到